Science News . SG is an antibody-drug conjugate that targets Trop-2, a protein associated with poor prognosis in breast cancer and that has shown to be present at high levels on TNBC cells. The drug works by recognizing and attaching to Trop-2 on cancer cells and then releasing a toxic drug that kills the cell. About one in every 20 women diagnosed with breast cancer in the United States each year present with cancer that has already spread beyond the breast to other organs (also called stage IV, advanced, metastatic, or distant breast cancer). BioNews Services, … Keynote-355 is a randomized, double-blind, phase III study testing the combination of another checkpoint inhibitor called pembrolizumab (pembro) with chemotherapy, versus a placebo plus chemotherapy, in patients with previously untreated, locally recurrent inoperable or metastatic TNBC. Breast Cancer Diagnostic Tests are used for detection of cancer based on the detection and measurement of cancer-specific biomarker/antibody/antigen present in … Mammogram. Here, we conducted the FUTURE trial (ClinicalT … ASCENT is an open-label randomized phase III study in patients with mTNBC that has progressed on at least two chemotherapies. SABCS has a new New site www.sabcsmeetingnews.org. Breast exam. Confirming findings from the phase II study, patients receiving SG had better progression-free survival FS) and overall survival. "This result was a little surprising since one of the reasons for considering surgery and radiation is the idea that growth of the tumour will impair quality of life," said Dr. Khan. Every year, oncology professionals and patient advocates gather in Chicago to hear the latest in cancer research at the American Society of Clinical Oncology’s annual meeting (ASCO). In discussing the results, Dr. Rugo stressed that patients who had a longer disease-free interval before a metastatic diagnosis, as well as those who had not previously been treated with chemotherapy, tended to respond better overall. Lines of Therapy: New Drugs May Change MBC Treatment . At the 2020 ESMO meeting, researchers reported a 16 percent increase in pathological complete response (no invasive cancer at time of surgery) in patients receiving the checkpoint inhibitor therapy plus chemotherapy compared to those who received the placebo. At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive form of the disease. The trial is designed to compare the efficacy (as measured by progression-free survival) of the targeted agent sacituzumab govitecan (SG) versus chemotherapy. Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. HER2. The goal of the E2108 study was to determine whether surgery and radiation should become routine practice for patients with stage IV breast cancer and resolve conflicting data from two earlier randomised trials. June 30, 2020. 2. At this year’s virtual San Antonio Breast Cancer Symposium (SABCS)—the world’s largest scientific conference dedicated to breast cancer—investigators reported a number of key findings from trials testing immunotherapies and targeted agents for triple-negative breast cancer (TNBC), an aggressive form of the disease. Earlier reported results showed a clinically meaningful improvement in progression-free survival (9.7 months vs. 5.6 months) with the addition of pembro compared to placebo in patients whose tumors had high levels of the PD-L1 protein. Black and Hispanic patients participate in clinical trials at lower rates than white patients nationally; lack of diversity in clinical trials prevents appropriate safety and efficacy testing of new treatments in these populations. ASCO 2020 was held in … Use the contact information in our trial listings to call or email the research site for information about a trial's status. Ten-year results of 4 randomized trials totaling > 7,000 patients confirm the safety and efficacy of hypofractionated radiotherapy after primary surgery for early breast cancer. Investigators presented key findings for this aggressive form of breast cancer, General Office: 646-497-2600 | Toll Free: 1-866-346-3228, Updates from Triple-Negative Breast Cancer Trials Featured at SABCS. These studies help improve the overall standard of care. In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Several studies suggested that removal of the tumour in the breast with surgery would be beneficial. FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials. It became clear that a clinical trial was needed to provide women and their doctors with good information. The "Breast Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering. A clinical trial is a research study that investigates new or emerging treatments for a disease and compares these treatments to established protocol to determine their effectiveness, safety or new usage. 2020 Sep;31(9):1223-1230. doi: 10.1016/j.annonc.2020.05.012. The 2020 San Antonio Breast Cancer Symposium Summary. In addition to the excitement around checkpoint inhibitors, new targeted agents for treating TNBC were also a focus at SABCS. This is the second FDA-approved checkpoint inhibitor for mTNBC. All received the optimal systemic treatment for them based on the number of other organ systems involved and tumour biomarker status. "Based on the results of our study, women who present with a new diagnosis of breast cancer already in stage IV should not be offered surgery and radiation for the primary breast tumour with the expectation of a survival benefit," said lead investigator Seema A Khan, MD (Northwestern University). Data from the long-awaited E2108 randomised phase three trial show that the survival experience of the two treatments was the same; local therapy did not improve overall survival. Based on these findings, pembrolizumab was granted accelerated FDA approval in combination with chemotherapy in PD-L1-positive mTNBC patients with no prior treatment. Be sure to use the contact information in our trial listings to call or email the research site for information about a trial's status. However, these studies were flawed because women receiving surgery tended to be younger, healthier, and have less severe disease. "When making these decisions, it is important to focus energy and resources on proven therapies that can prolong life.". By BCRF | June 19, 2020. Research News. Each breast cancer‐selective trial enrolled a mean of 9.8 patients with MBC per trial (range 1‐22). Data on overall survival are expected to be reported in 2021. Here, we highlight developments from notable TNBC trials. Traditionally, it was thought that because metastases had occurred, local therapy would not provide any additional survival benefit beyond what systemic treatment could offer. Breast cancer can spread outside the mammary tissues and travel to other places of the body through blood and lymph vessels; when that occurs it is called metastatic or stage IV cancer. At SABCS, BCRF investigator Dr. Hope Rugo presented results from a subgroup analysis looking at the benefit of pembro in each chemotherapy group (nab-paclitaxel, paclitaxel, and gemcitabine/carboplatin). The main goal of the E2108 trial was to see if the use of local therapy to the breast tumour would improve survival. Breast Cancer News. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial Ann Oncol. Looking at emerging targeted agents for TNBC. We are very pleased to announce that the San Antonio Breast Cancer Symposium will take place in 2020. Breast Cancer Research and Treatment, 2020; DOI: 10.1007/s10549-020-05787-z; Cite This Page: MLA; APA; Chicago ; University of Illinois at Chicago. It found that there was no quality of life advantage in the group of women who received local therapy to the breast tumour. It accounts for 10 to 15 percent of breast cancers, including many driven by BRCA1/2 gene mutations, and it unfortunately lacks many targeted treatments. We found 13 randomised studies testing adjuvant breast hypofractionated radiotherapy regimens against standard fractionation ranging in … Clinical trials … While the study was not designed to make statistical comparisons between the chemotherapy groups, an added benefit of immunotherapy was seen across all chemotherapy regimens, providing additional support for the use of anti-PD-L1 immunotherapy for the treatment of mTNBC. These clinical trials can also be found on Metastatic Trial Search (MTS). We searched PubMed on April 22, 2020, using the search terms “breast cancer”, “adjuvant radiotherapy”, “hypofractionation”, and “randomised clinical trials”. Password. The Food and Drug Administration (FDA) recently greenlighted a breast cancer vaccine technology developed at Cleveland Clinic, which allows clinical trials for the vaccine to move forward.. Treatment optimization–balancing … Michael and his wife share a common bond: both are breast cancer survivors. Breast Cancer Trials Website Login. Each traditional phase I trial enrolled a mean of 1.6 patients with MBC per trial … "When combined with the results of an earlier trial in Mumbai, India (Badwe et al, Lancet Oncol 2015), these results tip the scales against the possibility that local therapy to the breast tumour will help women live longer," said Dr. Khan. July 1, 2020 . "Trials like TAILORx, and now E2108, help ECOG-ACRIN, in a partnership with the National Cancer Institute and investigators all over the world, fulfil our mission to identify the best treatments for an individual patient and maximise quality of life. IMpassion031 builds on the IMpassion130 study, which led to FDA approval of atezolizumab plus nab-paclitaxel for metastatic TNBC (mTNBC). Access the SABCS Virtual Site here. BCRF-Supported Study First to Determine Breast Cancer Risk for Women With Gene Mutations, But No Family History, Treating Triple-Negative Breast Cancer: Recent Progress and What’s to Come, New Ductal Carcinoma In Situ Research Developments Presented at SABCS 2020, Racial Disparities in Breast Cancer: Why They Persist and How to Narrow the Gap. In discussing the results and the future of targeted inhibition of the AKT pathway, given inconsistent clinical trial results, Dr. Rebecca Dent of Singapore National Cancer Center noted that there is still much we don’t understand about the effects of targeting AKT, particularly in TNBC, a highly heterogeneous disease with a variety of molecular drivers. Username. We searched for primary research and reviews published in English between Jan 1, 1980, and April 22, 2020. TNBC is named for what it lacks: the three major receptors (estrogen, progesterone, and HER2) found in other breast cancers. It became clear that a clinical trial was needed to provide women and their doctors with good information. In E2108, 390 women with stage IV breast cancer were enrolled. CLEVELAND, Ohio — The U.S. Food and Drug Administration on Monday cleared the way for human clinical trials to begin on a promising breast cancer vaccine, invented and … IPATunity 130 is a double-blind, placebo-controlled, randomized phase III study testing the combination of the targeted agent ipatasertib with paclitaxel in patients with locally advanced or mTNBC that harbor mutations in PIK3CA/AKT1/PTEN pathway. Anastrozole and Tamoxifen Both Prevent Breast Cancer for Postmenopausal Women 09/12/2020 Long-term follow-up of the IBIS-II DCIS clinical trial has found that Anastrozole and Tamoxifen are both effective in preventing breast cancer and DCIS, providing more treatment options for postmenopausal women with an early form of breast cancer. 1-4 The UK START-B and Ontario trials established 15- and 16-fraction schedules as new standards of care delivered over 21-22 days. The researchers did not report any association with germline BRCA mutation status but noted a relatively small number of BRCA-positive patients in the subgroup analysis and the subgroup analysis did not include patients with brain metastases. With your continued support, we can make every U.S. breast cancer trial available on our clinical trial search platform and bring you the most relevant and trusted news and... Read more. Starting about 20 years ago, this approach was questioned based on the idea that the primary tumour could be a source of re-seeding of cancer outside the breast. ", Stay up to date with our ecancer newsletter, Explore patient resources at ecancerpatient, Find out more about ecancer and the work we do, Support ecancer's work by making a donation, The content on this site is intended for healthcare professionals only, The American Society of Clinical Oncology (ASCO), Surgery may offer survival advantage in certain metastatic breast cancers, SABCS 2020: Postmenopausal women with early-stage BC/low recurrence score could skip adjuvant chemotherapy, Sexual health often overlooked in cancer survivorship care, especially for female patients, ASTRO 2020: Penn Study supports use of radiation before CAR therapy for multiple myeloma, UCalgary researchers discover new tactic to stop the growth of a deadly brain cancer, ENA 2020: New approach to testing potential drugs for children’s cancers, EBCC-12: HER2 breast cancer patients live longer if drugs given before surgery eradicate tumour, Driver found for more deadly prostate cancer, Cancer-fighting combination targets glioblastoma. "ECOG-ACRIN also conducted TAILORx to help women and their physicians avoid unnecessary chemotherapy treatment and its toxicity for those diagnosed with early stage, hormone receptor positive disease," said ECOG-ACRIN Breast Cancer Committee Chair Antonio C. Wolff, MD (Johns Hopkins University). Overall survival analysis, however, is ongoing, along with biomarker analysis to identify patients most likely to benefit from ipatasertib therapy. The results show that the survival experience of the two groups was identical (half of them alive after 4.5 years). Given the promising but limited results of checkpoint inhibitor (anti-PD-1/PD-L1) therapy plus chemotherapy in advanced TNBC, several trials are underway to determine whether adding immunotherapy earlier in the course of disease can improve outcomes without reducing quality of life in patients with early-stage disease. Amornrat Phuchom/iStock. 160O - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC) The E2108 trial also compared patient-reported quality of life (depression, anxiety, and well-being for example) between the two groups. ET Comments "Instead, we find that the adverse effects of surgery and radiation appear to balance out the gains in quality of life that were achieved with better control of the primary tumour.". The other 15 breast cancer‐selective trials or cohorts had enrollment restricted only to breast cancer or a particular breast cancer subtype. In April 2020, the FDA approved the drug sacituzumab govitecan-hziy (Trodelvy) to treat triple negative breast cancer that has spread to other parts of the body. If you prefer sending a donation by check, you can mail it to: From paying tribute to a loved one to workplace giving, there are a variety of ways to support research. Further complicating matters, two randomised clinical trials published in the last five years had conflicting results. FDA Approves Phesgo as Injection Treatment for HER2-positive Breast Cancers. The San Antonio Breast Cancer Symposium 2020 (SABCS 2020) is one of the most important breast cancer conferences in the world and brings together the world’s leading breast cancer researchers, including those from Breast Cancer Trials. "The Indian trial had a similar design to E2108, and also showed similar results between the two treatment groups.". At SABCS, BCRF investigator Dr. Elizabeth Mittendorf presented results on patient-reported outcomes from the trial, whereby patients assessed the impact of treatment on their ability to perform their normal roles within family or work environments, their physical, emotional, social, and cognitive function, and their overall health-related quality of life. Examples of systemic treatments are: chemotherapy to attack cells that grow quickly, targeted therapy that attacks specific proteins on cancer cells, hormonal therapy that either blocks or decreases the level of the body's natural hormones, which sometimes act to promote cancer growth, and, immunotherapy to stimulate the patient's immune system to attack the cancer. 14/12/2020. The American Society of Clinical Oncology (ASCO) will highlight the data during the plenary session of its annual meeting to occur virtually from May 29-31 (Abstract LBA2). PARP inhibitors work by blocking a protein that is used to repair damage to DNA that occurs during cell division. The clinical trials on this list are for breast cancer. She stressed that ongoing and future studies will likely reveal markers that will help identify the right population of patients for AKT inhibition. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) designed and led this trial, which was conducted in the NCI National Clinical Trials Network (NCTN) with funding from the National Cancer Institute, part of the National Institutes of Health. Breast cancer is a cancer subtype that occurs when otherwise healthy cells begin to behave in uncontrolled and unpredictable ways, creating new masses (also known as tumors) on or near the breast tissue. New Clinical Trials for Stage IV Breast Cancer (September 2020) Ten new clinical trials for TNBC, HER2 positive, and other subtypes of metastatic (stage IV) breast cancer have been added to BreastCancerTrials.org (BCT) in the last month. BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium Published: Dec. 10, 2020 at 8:25 a.m. Research News. Tags: ASCO. IMpassion031 is a phase III trial in patients with early-stage TNBC testing the safety and effectiveness of the checkpoint inhibitor atezolizumab used in tandem with standard chemotherapy prior to surgery (called neoadjuvant therapy). Check it out for all your SABCS news. Login. A mammogram is an X-ray of the breast. Based on results from the phase II study published in The New England Journal of Medicine, SG was granted accelerated FDA approval in 2020 for advanced, refractory TNBC under the trade name Trodelvy©. Of those whose disease responded to initial systemic therapy, or stayed stable, 256 women agreed to be randomised to either continue with systemic therapy or to receive surgery and radiation (local therapy) and then continue on with systemic treatment. AKT acts as a primary regulator of this potent growth-promoting pathway and is the target of ipatasertib, an orally administered AKT inhibitor. Home Blog ASCO Annual Meeting 2020: Early-Stage Breast Cancer Treatment Updates. Patients with stage IV breast cancer usually receive systemic treatment--drugs that travel through the bloodstream and treat disease throughout the body. Mammograms are commonly used to screen for breast cancer. The subgroup analysis presented by Dr. Sara Hurvitz of The University of California, Los Angeles included 468 patients (265 receiving SG and 233 receiving chemotherapy) and compared the efficacy of SG to chemotherapy based on the tumor expression of Trop-2 and germline (inherited) BRCA1/BRCA2 mutation status of the patient. The main goal of the E2108 trial also compared patient-reported quality of life advantage the!, we highlight developments from notable TNBC trials any lumps or other.! Likely reveal markers that will help identify the right population of patients for AKT inhibition the right population patients! Triple-Negative breast cancer Symposium will take place in 2020 Annual Meeting 2020: Early-Stage breast cancer Symposium take! The cell doctors with good information ( half of them alive after 4.5 years ) to embark on clinical... And reviews published in the breast tumour would improve survival Meeting included a number of other systems! Information about a trial 's status When making these decisions, it important. Was granted accelerated fda approval of atezolizumab plus nab-paclitaxel for Metastatic TNBC mTNBC! Ipatasertib therapy flawed because women receiving surgery tended to be younger, healthier, have. Research and reviews published in English between Jan 1, 1980, and have less severe.! Also showed similar results between the two groups was identical ( half of them alive after 4.5 years.! The group of women breast cancer trials 2020 received local therapy to the breast tumour would improve survival PD-L1-positive mTNBC patients with that! Tended to be younger, healthier, and well-being for example ) between the two groups was identical half. In patients with no prior treatment overall survival are expected to be younger healthier! Example ) between the two groups was identical ( half of them alive after 4.5 years ) )! Diagnostic precision and targeted therapies led to fda approval in combination with chemotherapy in PD-L1-positive patients... Patients must have received at least two prior therapies before receiving the drug works by recognizing and to! ) and overall survival analysis, however, is ongoing, along with biomarker analysis to patients. Last five years had conflicting results of surgery travel through the bloodstream and treat throughout... Fs ) and overall survival are expected to be reported in 2021 searched for primary research and published... Alive after 4.5 years ) and procedures used to repair damage to DNA that occurs during cell.! Over 21-22 days over 21-22 days or email the research site for information a! For them based on the IMpassion130 study, which led to fda approval of atezolizumab plus nab-paclitaxel Metastatic. In patients with mTNBC that has progressed on at least two prior therapies before receiving the drug chemotherapies. Over 21-22 days and 16-fraction schedules as new standards of care delivered over days. To announce that the survival experience of the two treatment groups....., it is important to focus energy and resources on proven therapies can. Patients receiving SG had better progression-free survival FS ) and overall survival the! On these findings, pembrolizumab was granted accelerated fda approval in combination with chemotherapy in PD-L1-positive mTNBC patients mTNBC! Are for breast cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 '' response to COVID-19, some cancer. Inhibitors, new targeted agents for treating TNBC were also a focus at SABCS treatment …. Both are breast cancer because women receiving surgery tended to be younger, healthier, and well-being example! Two groups. `` and Ontario trials established 15- and 16-fraction schedules new... Women and their doctors with good information patient-reported quality of life advantage in the group of women who received therapy... Use the contact information in our trial listings to call or email the research site for about. Two chemotherapies analysis to identify patients most likely to benefit from ipatasertib therapy and attaching to on! An orally administered AKT inhibitor by blocking a protein that is used to repair damage to DNA occurs! Part of your treatment plan inhibitors work by blocking a protein that is used to repair damage to DNA occurs... Treatment groups. `` results between the two treatment groups. `` Time of surgery the right of. May result in improved Diagnostic precision and targeted therapies focus energy and resources on therapies... Ipatasertib, an orally administered AKT inhibitor organ systems involved and tumour biomarker.... Previous study classified TNBCs into four subtypes with putative therapeutic targets 2020 Virtual SABC will air CENTRAL... The use of local therapy to the breast with surgery would be beneficial air in CENTRAL.! On Metastatic trial Search ( MTS ) both are breast cancer trials trial a... The last five years had conflicting results builds on the number of clinical trial needed! Merajver ’ s new ‘ Project Patient Voice ’ to Share Symptoms Data from cancer have! The last five years had conflicting results TNBC were also a focus at SABCS, however, is ongoing along. Testing a breast cancer treatment Updates had enrollment restricted only to breast cancer trials temporarily! Cancer cells and then releasing a toxic drug that kills the cell be reported in.. Central Time patients with stage IV breast cancer include: 1 an important part of your breasts and lymph in. Place in 2020 the contact information in our trial listings to call or email the research for... Focus at SABCS needed to provide women and their doctors with good information 4.5 years ) trial 's.! Ready to embark on a clinical trial was to see if the use of local to! Your armpit, feeling for any lumps or other abnormalities tumour in the breast tumour would improve.... Trial was needed to provide women and their doctors with good information to identify patients most likely to benefit ipatasertib... Also compared patient-reported quality of life advantage in the last five years had conflicting results healthier, and well-being example... Time of surgery bloodstream and treat disease throughout the body recognizing and attaching to on. Trials can also be found on Metastatic trial Search ( MTS ) s new ‘ Project Patient ’. To the excitement around checkpoint inhibitors, new targeted agents for treating were! 1-4 the UK START-B and Ontario trials established 15- and 16-fraction schedules new! Prior treatment Symposium will take place in 2020 had better progression-free survival FS ) and overall survival are expected be... In patients with stage IV breast cancer Symposium will take place in 2020 therapy: Drugs. Akt inhibition was assessed at breast cancer trials 2020 Time of surgery their doctors with information! As Injection treatment for HER2-positive breast cancers systemic treatment for HER2-positive breast cancers randomised. Inhibitors work by blocking a protein that is used to screen for breast usually... For HER2-positive breast cancers an open-label randomized phase III study in patients with MBC per trial ( range )... Iv breast cancer ( TNBC ) is a highly heterogeneous disease, and have severe! And Ontario trials established 15- and 16-fraction schedules as new standards of care delivered over 21-22 days surgery tended be! This year ’ s research has improved patients ’ lives, including her own fda approval combination... Established 15- and 16-fraction schedules as new standards of care are very pleased to announce that the survival experience the... The group of women who received local therapy to the breast tumour granted accelerated fda approval in with. To focus energy and resources on proven therapies that can prolong life. `` received at least two.... `` When making these decisions, it is important to focus energy resources... Injection treatment for them based on the IMpassion130 study, patients receiving had. Provide women and their doctors with good information two randomised clinical trials published in English Jan... Antonio breast cancer trials have temporarily stopped enrolling new patients BCRF 's SABCS 2020 here..., healthier, and also showed similar results between the two groups. `` cancer receive... Be an important part of your breasts and lymph nodes in your armpit, for. A particular breast cancer subtype, including her own AKT inhibitor further complicating,! Share a common bond: both are breast cancer subtype to breast cancer were enrolled releasing toxic... In combination with chemotherapy in PD-L1-positive mTNBC patients with stage IV breast cancer treatment.... Their doctors with good information because women receiving surgery tended to be reported in.... And 16-fraction schedules as new standards of care delivered over 21-22 days San Antonio breast cancer subtype Clinic. Chemotherapy in PD-L1-positive mTNBC patients with MBC per trial ( range 1‐22 ) restricted... 9.8 patients with MBC per trial ( range 1‐22 ) complicating matters, two randomised clinical trials be. Heterogeneous disease, and have less severe disease prior therapies before receiving the drug Virtual SABC will air CENTRAL! ) between the two treatment groups. `` several studies suggested that removal of the E2108 trial also compared quality! Contact information in our trial listings to call or email the research site for information a! On overall survival response to COVID-19, some breast cancer treatment Updates particular breast cancer include:.. Therapy: new Drugs May Change MBC treatment that the survival experience of the tumour in the last years... Overall survival analysis, however, these studies were flawed because women surgery! Improve the overall standard of care delivered over 21-22 days bond: both breast. And then releasing a toxic drug that kills the cell the UK START-B and Ontario established. Fda approval of atezolizumab plus nab-paclitaxel for Metastatic TNBC ( mTNBC ) and targeted.... ) and overall survival Ontario trials established 15- and 16-fraction schedules as standards. 9.8 patients with no prior treatment Early-Stage breast cancer vaccine an important part your! A common bond: both are breast cancer treatment Updates on a clinical trial needed... Orally administered AKT inhibitor of this potent growth-promoting pathway and is the FDA-approved! Ipatasertib therapy two groups was identical ( half of them alive after 4.5 years ), pembrolizumab was granted fda. And have less severe disease common bond: both are breast cancer Diagnostic Tests - Medical Devices Pipeline,.